Article

Lower birthweight criterion suggested for ROP screenings

A birthweight of 1,250 g may be a dependable criterion for screening for retinopathy of prematurity (ROP) and also might reduce the number of examinations, suggested Shailesh K. Gupta, MD, University of Florida College of Medicine, Jacksonville. Current guidelines recommend screening of infants under 1,500 g or a gestational age of less than 28 weeks.

Chicago-A birthweight of 1,250 g may be a dependable criterion for screening for retinopathy of prematurity (ROP) and also might reduce the number of examinations, suggested Shailesh K. Gupta, MD, University of Florida College of Medicine, Jacksonville. Current guidelines recommend screening of infants under 1,500 g or a gestational age of less than 28 weeks.

Dr. Gupta based this conclusion on a retrospective study of 208 infants screened for ROP over a period of 2 years at a large academic medical center. The infants were divided into group 1 (n = 158), whose birthweight was less than or equal to 1,250 g, and group 2 (n = 50), whose birthweight was more than 1,250 g. The mean gestational age of infants in group 1 was 26.8 weeks; it was 30 weeks in group 2. Investigators found 116 eyes with ROP in group 1 and one case in one eye in group 2.

They analyzed numerous factors, including the maximum stage of ROP, and calculated sensitivity, specificity, and positive predictive value.

“The advantage of decreasing screening criteria to 1,250 g is that it increases the efficiency of ROP screenings. In our data set, it decreased screenings by 24% and decreased the expense,” Dr. Gupta said. He noted that multicenter studies of this hypothesis are needed and that future analyses need to take into account the racial and ethnic backgrounds of the infants.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.